Global Dysphagia Market, By Type (Esophageal Dysphagia, Oral Dysphagia, Pharyngeal Dysphagia), Treatment Type (Medicines, Surgery), Route of Administration (Oral, Parenteral, Others), Diagnosis (Manometry, Endoscopy, Barium Swallow Test, Swallow Study, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the dysphagia market is anticipated to proliferate during the forecast period. According to the World Heart Association, the global incidence rate of stroke is 15 million, with 6 million people dying and another 6 million becoming disabled, resulting in vision loss and speech impairment. As a result, the rising prevalence of stroke-related dysphagia and associated pharyngeal and laryngeal problems is propelling the dysphagia market forward. Cerebrovascular accidents (strokes) are caused by insufficient blood supply (oxygen and nutrients) to the brain.
Data Bridge Market Research analyses that the dysphagia market was valued at USD 3.05 billion in 2021 and is expected to reach USD 4.62 billion by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Dysphagia is a condition in which people have trouble swallowing food. The ability to swallow safely is critical for proper nutrition and hydration as well as preventing food from entering the lungs. Swallowing is a complicated act that requires coordinated muscular activity in three basic phases: oral phase (mouth), pharyngeal phase (throat), and esophageal phase (food tube). Dysphagia is a condition that occurs when one or more of these stages are disrupted. Food texture modifying products and other products such as tubes are used to aid in the swallowing process in dysphagia management.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Esophageal Dysphagia, Oral Dysphagia, Pharyngeal Dysphagia), Treatment Type (Medicines, Surgery), Route of Administration (Oral, Parenteral, Others), Diagnosis (Manometry, Endoscopy, Barium Swallow Test, Swallow Study, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Dr. Reddy's Laboratories Ltd. (India), Cipla Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Zydus Cadila (India), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), WOCKHARDT (India), Lannett (US), Cook (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Fresenius Kabi AG (Germany), BD (US), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Johnson & Johnson Private Limited (US)
|
|
Market Opportunities
|
|
Dysphagia Market Dynamics
Drivers
- Rising number of people addicted to smoking
The rising number of people addicted to smoking is anticipated to influence the dysphagia market's growth during the forecast period. One of the most serious adverse effects of smoking cigarettes for an extended period of time is dysphagia. While tobacco use kills approximately 6 million people each year, the rising prevalence of oropharyngeal cancer is progressively fueling the expansion of the dysphagia market.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of dysphagia market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the dysphagia market. Additionally, high disposable income and surging demand for dysphagia management in healthcare services and medical facilities will expand the dysphagia market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the dysphagia market growth.
Moreover, the rising focus of market players on launching OTC drugs to treat dysphagia and increase in the number of emerging markets will further provide beneficial opportunities for the dysphagia market growth during the forecast period.
Restraints/Challenges
- Difficulty in the diagnosis of dysphagia
However, difficulty in the diagnosis of exact cause of dysphagia is anticipated to obstruct the market's growth rate. A variety of factors can cause dysphagia, and determining the cause can be challenging in some circumstances.
On the other hand, the high cost associated with the treatment will obstruct the growth rate of market. The dearth of awareness among people and lack of healthcare infrastructure in developing economies will challenge the dysphagia market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of advanced therapies for dysphagia will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This dysphagia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dysphagia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
In the United States, around 15 million people suffer from dysphagia. Dysphagia affects about 1 in every 25 persons throughout their lives.
Dysphagia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Dysphagia Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of dysphagia in recent months.
Recent Development
- In September 2020, Thick-It Brand announced the launch of a variety pack of dysphagia nutrition products. Purée Protein, Purée Vegetable, and Ready-to-Drink are all available in the new packets. The ready-to-drink alternatives are available in IDDSI Level 2 – Mildly Thick (nectar) and IDDSI Level 3 – Moderately Thick (honey) consistencies and feature the newly reformulated Thick-It Clear Advantage drinks. Purées can be found in IDDSI Level 4 – Puree.
Global Dysphagia Market Scope
The dysphagia market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Esophageal Dysphagia
- Oral Dysphagia
- Pharyngeal Dysphagia
Treatment
- Medicines
- Surgery
Route of Administration
- Oral
- Parenteral
- Others
Diagnosis
- Manometry
- Endoscopy
- Barium Swallow Test
- Swallow Study
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Dysphagia Market Regional Analysis/Insights
The dysphagia market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the dysphagia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the dysphagia market because of the growing prevalence of dysphagia and presence of refined healthcare expenditure in this region. Additionally, growing focus of major key players on novel technology is projected to propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to the increasing number of generic manufacturers and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Dysphagia Market Share Analysis
The dysphagia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dysphagia market.
Some of the major players operating in the dysphagia market are:
- Dr. Reddy's Laboratories Ltd. (India)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Dr. Reddy's Laboratories Ltd. (India)
- Cipla Inc. (US)
- Zydus Cadila (India)
- WOCKHARDT (India)
- Lannett (US)
- Cook (US)
- Fresenius Kabi AG (Germany)
- BD (US), Eisai Co., Ltd. (Japan)
SKU-